While reporting financial results for the fourth quarter on Tuesday, biopharmaceutical company Merck & Co., Inc. (MRK), known as MSD ...

Morgan Stanley analyst Terence Flynn lowered the firm’s price target on Merck (MRK) to $106 from $113 and keeps an Equal Weight rating on the ...

Merck said on Tuesday it would not ship its HPV vaccine Gardasil in China until at least the middle of this year due to weak ...

Welcome to the Merck & Company Q4 sales and earnings conference call. [Operator instructions] This call is being recorded.

Merck’s full-year 2025 revenue guidance fell short of what some analysts were expecting, at a range of $64.1 billion to $65.6 ...

Wall Street rebounds as tech stocks surge, with the S&P 500 up 0.5% amid easing trade tensions and strong corporate earnings.

Merck said it expected sales of $64.1 billion to $65.5 billion in 2025 and adjusted earnings of $8.88 to $9.03 a share. Both forecasts came in below the average analyst expectation for revenue of ...

Jan 24 (Reuters) - Merck (MRK.N), opens new tab and Japan-based Eisai (4523.T), opens new tab said on Friday a combination of their therapies failed to extend the lives of patients with a type of ...

Merck & Company Inc (NYSE:MRK) shares tumbled more than 8% on pre-market trading on Tuesday after reporting mixed fourth-quarter results, with earnings falling short of expectations, revenue ...

Mr. Kennedy has referred clients to the firm in cases claiming injuries from the Gardasil vaccine, a Merck product that is meant to prevent cervical cancer that can be caused by the human ...

The 80-patient placebo-controlled randomized Phase 2 study will evaluate the efficacy of opaganib in combination with Bayer's darolutamide in men with metastatic castrate-resistant prostate cancer ...